Antipsychotic Cross-Titration
On this page
Direct answer
Risperidone's prolactin burden often forces a switch to aripiprazole, and how that switch is executed decides whether the psychosis stays controlled: the standard method is cross-titration, building the new drug up while tapering the old one down over one to two weeks, so dopamine blockade never falls below therapeutic. Abrupt discontinuation is reserved for medical emergencies such as neuroleptic malignant syndrome. Special rules apply at the edges — clozapine interrupted for more than 48 hours must be re-titrated from a low dose, and long-acting injectables need defined oral overlap, famously three weeks for risperidone microspheres. Stopping drugs with anticholinergic or histaminic action produces recognisable rebound syndromes the switcher must anticipate.
What you must remember
- Three switching methods: cross-titration (overlap, safest for relapse prevention), abrupt switch (medical necessity only), and the intermediate stop-then-start; know the names as they appear in guidelines.
- Clozapine rule: if clozapine is interrupted for more than 48 hours (some protocols say one day), restart at a lower dose and retitrate — the risk is respiratory and cardiac, plus seizure threshold reset.
- LAI overlap arithmetic: risperidone long-acting injection needs about 3 weeks of continued oral antipsychotic after the first injection; paliperidone palmitate with its day-1 and day-8 loading doses (233 mg and 156 mg deltoid) needs no routine oral supplementation — a favourite contrast.
- Anticholinergic rebound: stopping clozapine, olanzapine or low-potency phenothiazines (or their anticholinergic cover) abruptly can cause nausea, sweating, insomnia, restlessness and even psychosis — manage with gradual taper or transient anticholinergic cover.
- Rebound insomnia: quetiapine and olanzapine withdrawal commonly produces severe insomnia from histamine H1 receptor rebound; warn the patient rather than misreading it as relapse.
- Reason dictates pace: switches for intolerable side-effects (tardive dyskinesia, NMS) move fast or wash out; switches for inefficacy always overlap.
- Check the destination: know the target dose before starting — a switch executed to a sub-therapeutic new drug is a hidden discontinuation trial.
Planning the switch, end to end
Take a 45-year-old woman stabilised on haloperidol 10 mg with debuting orofacial tardive dyskinesia; the destination is olanzapine. Days 1-7: start olanzapine 5 mg at night while haloperidol drops to 5 mg; the overlap keeps D2 occupancy from dipping into the sub-therapeutic range where relapse lives. Days 8-14: olanzapine to 10 mg, haloperidol to 2 mg, then stop; oral anticholinergic cover, if she was on it, tapers last and slowest to avoid cholinergic rebound. A follow-up at week four — not month four — checks both efficacy and the metabolic panel olanzapine now demands.
The mirror case is a patient with schizophrenia doing well on oral aripiprazole but forgetting doses: conversion to a long-acting injectable. Choosing risperidone microspheres commits her to three weeks of oral overlap, which is exactly when busy clinics err by stopping the tablets on injection day. Choosing paliperidone palmitate avoids that window through front-loaded kinetics. And in every plan, the possibility of switching to clozapine is flagged early, because clozapine initiation conventionally follows a washout of the previous antipsychotic's one to two half-lives rather than a routine cross-taper, and haematological monitoring enrolment precedes the first dose.
How the exam frames it
Three fact-anchors dominate. The clozapine re-titration rule after a gap (48 hours is the number to quote). The LAI oral-supplementation table, where "risperidone Consta — 3 weeks oral overlap" is the classic single-best-answer against paliperidone palmitate, which loads on days 1 and 8 without oral cover. And the rebound syndromes: a vignette of severe insomnia and nausea two days after stopping quetiapine is testing histaminic and cholinergic rebound, not relapse — the discriminating clue is the tempo, far too fast for psychosis to return.
Frequently asked questions
What is cross-titration when switching antipsychotics?
Overlapping the two drugs — the new antipsychotic titrated upward while the old one is tapered over one to two weeks — so that dopamine blockade never falls below the therapeutic range.
When must an antipsychotic be stopped abruptly rather than cross-tapered?
In medical emergencies such as neuroleptic malignant syndrome or severe idiosyncratic reactions, where continuing the offending drug is dangerous.
What happens if clozapine is interrupted for more than 48 hours?
The dose must be re-titrated from a lower starting point rather than resumed at the previous dose, to reduce risks of hypotension, seizures and cardiac effects.
Which long-acting injectable requires oral antipsychotic supplementation, and for how long?
Risperidone long-acting microspheres require continued oral therapy for approximately three weeks after the first injection, whereas loading-dose paliperidone palmitate generally does not.
What is anticholinergic rebound?
A withdrawal syndrome of nausea, sweating, insomnia, headache and restlessness after abrupt cessation of anticholinergic drugs or antipsychotics with anticholinergic action, managed by gradual tapering or temporary cover.